WelChol: New Study Finds Additional LDL-C Drops When WelChol(R) (colesevelam HCl) Is Added to Fenofibrate in Patients With Mixed Hyperlipidemia
5th Oct 2005, 13:15 GMT
PARSIPPANY, NJ (MARKET WIRE) A new study published in the September 2005 issue of Current Medical Research and Opinion demonstrated that the addition of WelChol(R) (colesevelam HCl) to a stable dose of fenofibrate (e.g. TriCor(R)(1)) in patients with mixed hyperlipidemia lowered LDL-C, or "bad" cholesterol, levels by an additional mean 12.4 percent (p < 0.0001).
WelChol: New Study Finds Additional LDL-C Drops When WelChol(R) (colesevelam HCl) Is Added to Fenofibrate in Patients With Mixed Hyperlipidemia related news:
- New Study Finds Additional LDL-C Drops When WelChol(R) (colesevelam HCl) Is Added to Fenofibrate in Patients With Mixed Hyperlipidemia — ArriveNet : Health
- New Study Finds Additional LDL-C Drops When WelChol is Added to Fenofibrate in Patients with Mixed Hyperlipidemia — Insurance/ Managed Care News from StratCenter.com
- Lancet publishes proactive study: Diabetes treatment reduces risk of heart attacks & strokes — KeralaNext: Science
- Large sinus tumors can be removed endoscopically, study finds — EurekAlert! - Medicine and Health
- X-Rays Can Miss Spinal Damage (HealthDay) — Yahoo! Health: Back Pain News
- International study finds one in five heart patients continue to smoke — EurekAlert! - Medicine and Health
- Study Suggests More May Benefit From Clot-Busting Drug — Rednova News - Health
- The Lancet Publishes Groundbreaking Proactive Study Showing Type-2 Diabetes Treatment Significantly Reduces Risk of Non-Fatal Heart Attacks, Strokes and Deaths — Presseportal.de Wirtschaft
- Study finds patients with melanoma are at increased risk for new tumors — EurekAlert! - Cancer
- Music Might Help Heart Disease And Stroke Patients — KOMO - HealthWatch
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech